Targeted therapies for cutaneous T-cell lymphomas

Jason B. Kaplan*, Joan Guitart, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Cutaneous T-cell lymphomas (CTCLs) comprise a clinicopathologically heterogeneous group of uncommon non-Hodgkin lymphomas that manifest primarily in the skin but also may involve lymph nodes, blood, bone marrow and viscera. CTCLs are generally considered incurable unless allogeneic stem cell transplantation is implemented. Goals of therapy are to control symptoms, maintain cosmesis and improve survival by maximally reducing the tumor burden. Current treatment consists of skin-directed therapy for early stage disease and systemic therapy for advanced stage or refractory early stage disease. Despite the availability of a number of active systemic therapeutic strategies, including biological therapy, cytotoxic chemotherapy and extracorporeal photophoresis, there is an unmet need for targeted therapies, with favorable therapeutic indices, for the treatment of advanced and refractory CTCLs, which often render patients highly susceptible to infection. This review will discuss targeted therapy for the two most extensively studied subtypes of CTCL, mycosis fungoides and Sézary syndrome.

Original languageEnglish (US)
Pages (from-to)481-493
Number of pages13
JournalExpert Review of Hematology
Issue number4
StatePublished - Aug 2014


  • Sézary syndrome
  • cutaneous T-cell lymphoma
  • histone deacetylase inhibitor
  • immune checkpoint inhibitor
  • immunoconjugate
  • mycosis fungoides
  • proteasome inhibitor
  • targeted therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Targeted therapies for cutaneous T-cell lymphomas'. Together they form a unique fingerprint.

Cite this